Harbin Pharmaceutical Group Co., Ltd.

Shanghai Stock Exchange 600664.SS

Harbin Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 62.87 M

Harbin Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities is USD 62.87 M for the year ending December 31, 2023, a -10.21% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Harbin Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 70.02 M, a -21.56% change year over year.
  • Harbin Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 89.26 M, a 5.52% change year over year.
  • Harbin Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 84.59 M, a 19.95% change year over year.
  • Harbin Pharmaceutical Group Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 70.52 M, a -7.91% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Loading...
Shanghai Stock Exchange: 600664.SS

Harbin Pharmaceutical Group Co., Ltd.

CEO Mr. Bo Jiang
IPO Date June 29, 1993
Location China
Headquarters No. 68, Limin West Fourth Street
Employees 9,853
Sector Health Care
Industries
Description

Harbin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and trade of pharmaceuticals in China and internationally. The company operates through seven segments: Antibiotics, Small-Molecular Drug Preparations, OTC and Healthcare Products, Modern Chinese Medicines, Biopharmaceuticals, Animal Vaccines, and Medicine Circulations. It offers a series of penicillin and cephalosporin products, as well as intermediates. The company's lead products include Shuang Huanglian freeze-dried injection; Danshen freeze-dried injection; Shuang Huanglian powder for injection; roxithromycin dispersible tablets; belladonna, sulfamethoxazole, and trimerhoprim tablets; pediatric paracetamol, atificial cow-bezoar, and chlorphenamine maleate granules; Shuanghuanglian oral liquid; and ceftriaxone sodium for injection. Its lead products also comprise amoxicillin capsules, cefotiam hydrochloride for injection, panax ginseng extract, cefepime hydrochloride for injection, cefoperazone sodium for injection, and amoxicillin sodium and clavulanate potassium for injection; cefuroxime sodium, ceftazidime, cefotaxime sodium, and ceftriaxone sodium for injections; and ampicillin capsules. In addition, the company offers medical protective and disposable surgical masks, medical disposable protective gowns, and isolation gowns. It offers its products under the Hongyan Yaopin, Guangwei, Renmin Tongtai, Hayao Shengwu, Baohulu, Manshanhong, Hutong, Hayaoliu, Gaizhonggai, Sanchine, Shiyitang, and Hayao brands. The company is based in Harbin, China.

Similar companies

600812.SS

North China Pharmaceutical Company Ltd.

USD 0.69

4.15%

600643.SS

Shanghai Aj Group Co.,Ltd

USD 0.66

3.88%

600642.SS

Shenergy Company Limited

USD 1.21

0.80%

600649.SS

Shanghai Chengtou Holding Co.,Ltd

USD 0.58

2.17%

600795.SS

GD Power Development Co.,Ltd

USD 0.59

1.90%

StockViz Staff

January 15, 2025

Any question? Send us an email